13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
55 檔
30.8%
As reported in its official Q1 2026 Form 13F filing, Exome Asset Management LLC's tracked investment portfolio stood at $162.1M with 55 total positions.
In Q1 2026, Exome Asset Management LLC adopted a defensive or profit-taking posture, trimming 24 positions and completely liquidating 27 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 7.58% | -1.96% | -21.77% | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 5.54% | -0.51% | -8.85% | |
| 3 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.46% | -1.32% | -1.00% | |
| 4 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 4.27% | +0.04% | -5.54% | |
| 5 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 3.96% | -3.96% | EXIT | |
| 6 | GH | Guardant Health Inc | Stock-Healthcare | 3.95% | +2.30% | -15.73% | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.54% | -0.38% | -16.86% | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 3.34% | +0.72% | -10.70% | |
| 9 | ALMS | Alumis Inc | Stock-Other | 3.18% | +0.37% | -4.47% | |
| 10 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.59% | -1.75% | -16.39% | |
| 11 | VERA | Vera Therapeutics Inc | Stock-Other | 2.39% | +0.19% | -7.56% | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 2.25% | -1.34% | — | |
| 13 | ELV | Elevance Health Inc | Stock-Healthcare | 2.22% | -2.22% | EXIT | |
| 14 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.19% | -0.58% | -8.68% | |
| 15 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.16% | -0.35% | -8.22% | |
| 16 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.08% | -0.08% | — | |
| 17 | ✓ | Cytokinetics Inc | Stock-Other | 2.05% | -2.05% | EXIT | |
| 18 | NTRA | Natera Inc | Stock-Healthcare | 1.93% | +0.38% | — | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.83% | +0.38% | — | |
| 20 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.80% | +0.66% | +120.43% | |
| 21 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.78% | -1.78% | EXIT | |
| 22 | VSTM | Verastem Inc | Stock-Other | 1.75% | -0.74% | +58.48% | |
| 23 | TXG | 10x Genomics Inc-class A | Stock-Other | 1.69% | +0.74% | -5.78% | |
| 24 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.57% | -0.30% | — | |
| 25 | ALKS | Alkermes plc | Stock-Healthcare | 1.54% | +0.44% | — | |
| 26 | ✓ | Beigene LTD | Stock-Other | 1.54% | -1.54% | EXIT | |
| 27 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 1.53% | +0.52% | — | |
| 28 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.52% | -0.32% | — | |
| 29 | ADAG | Adagene Inc-adr | Stock-Other | 1.49% | -0.22% | -30.50% | |
| 30 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.48% | +0.14% | -8.11% | |
| 31 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.46% | -0.04% | — | |
| 32 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.43% | -0.88% | — | |
| 33 | ✓ | Ideaya Biosciences Inc | Stock-Other | 1.38% | -1.38% | EXIT | |
| 34 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.37% | +0.74% | — | |
| 35 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.27% | -0.21% | -30.03% | |
| 36 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.23% | -1.23% | EXIT | |
| 37 | ✓ | Alumis Inc | Stock-Other | 1.20% | -1.20% | EXIT | |
| 38 | GKOS | Glaukos CORP | Stock-Healthcare | 1.16% | +0.55% | -33.67% | |
| 39 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.14% | -0.07% | +67.79% | |
| 40 | PEN | Penumbra Inc | Stock-Healthcare | 1.07% | +0.16% | -30.00% | |
| 41 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.07% | -1.07% | EXIT | |
| 42 | LQDA | Liquidia CORP | Stock-Other | 0.89% | +1.04% | -49.76% | |
| 43 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.82% | — | — | |
| 44 | ✓ | Liquidia Corporation | Stock-Other | 0.78% | -0.78% | EXIT | |
| 45 | NBP | Novabridge Biosciences | Stock-Other | 0.73% | -0.04% | +15.49% | |
| 46 | ✓ | Centessa Pharmaceuticals PLC | Stock-Other | 0.71% | -0.71% | EXIT | |
| 47 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.63% | -0.63% | EXIT | |
| 48 | NXTC | Nextcure Inc | Stock-Other | 0.63% | -0.63% | EXIT | |
| 49 | PALI | Palisade Bio Inc | Stock-Other | 0.54% | -0.54% | EXIT | |
| 50 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.38% | +0.31% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ELVN | Enliven Therapeutics Inc | +2.8% | -1.00% | Trim |
| 2 | ALMS | Alumis Inc | +1.8% | -4.47% | Trim |
| 3 | ✓ | Alumis Inc | +1% | +97.37% | Add |
| 4 | UNH | Unitedhealth Group Inc | +0.9% | +120.43% | Add |
| 5 | CRBP | Corbus Pharmaceuticals Holdi | +0.6% | +67.79% | Add |
| 6 | ADAG | Adagene Inc-adr | +0.5% | -30.50% | Trim |
| 7 | TXG | 10x Genomics Inc-class A | +0.4% | -5.78% | Trim |
| 8 | AGIO | Agios Pharmaceuticals Inc | +0.4% | -8.68% | Trim |
| 9 | UTHR | United Therapeutics CORP | +0.4% | -8.22% | Trim |
| 10 | COGT | Cogent Biosciences Inc | +0.4% | -8.85% | Trim |
| 11 | VSTM | Verastem Inc | +0.3% | +58.48% | Add |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | +0.2% | -37.05% | Trim |
| 13 | ABUS | Arbutus Biopharma CORP | 0% | — | Unchanged |
| 14 | ✓ | Establishment Labs Holdings In | -0.1% | — | Unchanged |
| 15 | ARWR | Arrowhead Pharmaceuticals In | -0.1% | -8.11% | Trim |
| 16 | NTRA | Natera Inc | -0.1% | — | Unchanged |
| 17 | IONS | Ionis Pharmaceuticals Inc | -0.1% | -5.54% | Trim |
| 18 | ISRG | Intuitive Surgical Inc | -0.2% | — | Unchanged |
| 19 | NBP | Novabridge Biosciences | -0.2% | +15.49% | Add |
| 20 | CYTK | Cytokinetics Inc | -0.3% | -16.86% | Trim |
| 21 | CTMX | Cytomx Therapeutics Inc | -0.3% | -30.03% | Trim |
| 22 | PEN | Penumbra Inc | -0.3% | -30.00% | Trim |
| 23 | PALI | Palisade Bio Inc | -0.3% | -20.87% | Trim |
| 24 | BBIO | Bridgebio Pharma Inc | -0.4% | -16.39% | Trim |
| 25 | NXTC | Nextcure Inc | -0.5% | -30.00% | Trim |
| 26 | GKOS | Glaukos CORP | -0.5% | -33.67% | Trim |
| 27 | PRAX | Praxis Precision Medicines I | -0.6% | -21.77% | Trim |
| 28 | LQDA | Liquidia CORP | -0.6% | -49.76% | Trim |
| 29 | VERA | Vera Therapeutics Inc | -0.6% | -7.56% | Trim |
| 30 | ELV | Elevance Health Inc | -0.7% | -14.62% | Trim |
| 31 | LLY | Eli Lilly & Co | -0.7% | -10.70% | Trim |
| 32 | GH | Guardant Health Inc | -0.8% | -15.73% | Trim |
| 33 | ✓ | Travere Therapeutics Inc | -1.1% | -73.23% | Trim |
| 34 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 35 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 36 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 37 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 38 | INSM | Insmed Inc | — | NEW | New buy |
| 39 | IMVT | Immunovant Inc | — | EXIT | Sold out |
| 40 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 41 | ✓ | Cytokinetics Inc | — | NEW | New buy |
| 42 | UHS | Universal Health Services-b | — | EXIT | Sold out |
| 43 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 44 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 45 | CELC | Celcuity Inc | — | EXIT | Sold out |
| 46 | TVTX | Travere Therapeutics Inc | — | EXIT | Sold out |
| 47 | DXCM | Dexcom Inc | — | EXIT | Sold out |
| 48 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 49 | ALKS | Alkermes plc | — | NEW | New buy |
| 50 | ✓ | Beigene LTD | — | NEW | New buy |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 55 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, COGT, ELVN) accounted for 30.8% of total reported equity market value during Q1 2026.
Top New Position Initiated
XBI
市值: $7.7M
Top Position Liquidated / Trimmed
WVE
前期市值: $7.2M
During Q1 2026, Exome Asset Management LLC's top holdings by market value included PRAX (7.6%)、COGT (5.5%)、ELVN (4.5%). The largest single position, PRAX, represented 7.6% of total portfolio value.
In Q1 2026, Exome Asset Management LLC made 78 total portfolio adjustments, initiating 22 new buys, adding to 5 positions, trimming 24 holdings, and fully liquidating 27 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.